Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. HALAVEN
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

HALAVEN

Medicine - Posted on Nov 30 2018 - Updated on Jun 12 2019
Active substance (DCI)
  • éribuline (mésilate de)
history (4)
  • 11/21/18

    HALAVEN (éribuline), antinéoplasique

    Intérêt clinique important dans le cancer du sein, avancé ou métastatique, mais pas d’avantage clinique démontré par rapport...
    CAV :
    54321
    icône flèche
  • Economic analysis
    5/3/17

    HALAVEN (eribulin), antineoplastic agent

    Moderate clinical added value relative to dacarbazine as a monotherapy in advanced or metastatic unresectable liposarcoma in...
    CAV :
    54321
    icône flèche
  • Economic analysis
    9/23/15

    HALAVEN (eribulin), antineoplastic agent

    No clinical benefit demonstrated in the second-line treatment of locally advanced or metastatic breast cancer in patients in...
    CAV :
    54321
    icône flèche
  • 7/20/11

    HALAVEN

    -
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • L01XX41
Manufacturer
EISAI SAS
Presentation

HALAVEN 0,44 mg/ml, solution injectable (code CIS : 63816522) : 1 flacon(s) en verre de 2 ml - Code CIP : 3400941835230 / 6 flacon(s) en verre de 2 ml - Code CIP : 3400941835469

All our publications
    Breast cancers Drug therapy Health economics Skin and connective tissue cancers

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
CyEcM4sd7rGxUcjT